BLOOD PACK WITH ANT

CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED: CONTINUED ON NEXT PAGE PAGE 5 OF 24 PAGES SPE2DP-24-T-1875 SECTION A Procurement History for NSN/FSC:015998028/6505 CAGE Contract Number Quantity Unit Cost AWD Date Surplus Material . 4Q7Q2 SPE2DP21V0340 1.000 760.38000 20201216 N 4Q7Q2 SPE2DP21P0143 1.000 760.38000 20201021 N 4Q7Q2 SPE2DP20P1211P00001 5.000 734.40000 20200922 N 4Q7Q2 SPE2DP20V0111 4.000 734.40000 20191126 N 4Q7Q2 SPE2DP20P0110 2.000 734.40000 20191105 N 4Q7Q2 SPE2DP19V0702 6.000 713.40000 20190805 N 4Q7Q2 SPE2DP19V0377 1.000 713.40000 20190325 N 4Q7Q2 SPE2DP18V0873 4.000 692.40000 20180919 N 4Q7Q2 SPE2DP18V0740 5.000 692.40000 20180731 N 4Q7Q2 SPE2DP15M0045 2.000 630.99000 20141031 N 4Q7Q2 SPE2DP15V0109 2.000 630.99000 20141023 N 1Y3X1 SPE2DP14V0659P00001 1.000 899.00000 20140707 N CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED: CONTINUED ON NEXT PAGE PAGE 6 OF 24 PAGES SPE2DP-24-T-1875 SECTION B PR: 7006933334 NSN/MATERIAL:6505015998028 ITEM

DESCRIPTION BLOOD PACK WITH ANT BLOOD PACK WITH ANTICOAGULANT CITRATE . RA001: THIS DOCUMENT INCORPORATES TECHNICAL AND/OR QUALITY REQUIREMENTS (IDENTIFIED BY AN 'R' OR AN 'I' NUMBER) SET FORTH IN FULL TEXT IN THE DLA MASTER LIST OF TECHNICAL AND QUALITY REQUIREMENTS FOUND ON THE WEB AT: http://www.dla.mil/HQ/Acquisition/Offers/eProcurement.aspx FOR SIMPLIFIED ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE SOLICITATION ISSUE DATE OR THE AWARD DATE CONTROLS. FOR LARGE ACQUISITIONS, THE REVISION OF THE MASTER IN EFFECT ON THE RFP ISSUE DATE APPLIES UNLESS A SOLICITATION AMENDMENT INCORPORATES A FOLLOW-ON REVISION, IN WHICH CASE THE AMENDMENT DATE CONTROLS. RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT RQ011: REMOVAL OF GOVERNMENT IDENTIFICATION FROM NON-ACCEPTED SUPPLIES RX ONLY, STERILE AND NON-PYROGENIC, FOR INTRAVENOUS ADMINISTRATION. . SINGLE BLOOD PACK UNIT; DOES NOT INCLUDE FILTER; SINGLE USE ONLY. . CONFIGURATION: SINGLE ANTICOAGULANT/ADDITIVE SOLUTION: CITRATE PHOSPHATE DEXTROSE (CPD) PRIMARY CONTAINER VOLUME: 450 MILLILITERS (ML) USES A PL 146 PRIMARY CONTAINER . EACH UNIT CONSISTS OF A PL 146 PLASTIC PRIMARY CONTAINER WITH 63 ML OF CPD SOLUTION CONTAINING 1.66 G SODIUM CITRATE (DIHYDRATE) USP, 1.61 G DEXTROSE (MONOHYDRATE) USP, 188 MG CITRIC ACID (ANHYDROUS) USP, 140 MG MONOBASIC SODIUM PHOSPHATE (MONOHYDRATE) USP. . INCLUDES INTEGRAL DONOR TUBE AND 16 GAUGE ULTRA-THIN WALL NEEDLE . SUPPLIED AS ONE UNIT PER POUCH WITH 60 POUCHES PER CASE OR PACKAGE UNIT OF ISSUE IS A PACKAGE CONTAINING 60 EACH (SINGLE BLOOD PACK UNITS) . . STORE AT 20° TO 25°C (68° TO 77°F) SEE USP CONTROLLED ROOM TEMPERATURE . LABELING AND MARKING MUST IN ACCORDANCE WITH MEDICAL MARKING STANDARD NO. 1A DATED 4 FEBRUARY 2013 . 10/10/2016 . This device or drug is regulated by the FDA. Note to Buyers: The contracting official shall send a referral in EBS to the product specialist for confirmation. Please include bidder name and bidder contact information, manufacturer name, manufacturer part number, and item description. RS016: Shelf-life requirement RS001 for a TYPE I (CODE M) item with a shelf life of 24 months (non-extendable) applies to this item. APPLICABLE TO ALL MEDICAL ACQUISITIONS: PACKAGING AND PACKING SHALL BE COMMERCIAL AS SPECIFIED IN THE PROCUREMENT DOCUMENT. EACH COMPLETE UNIT SHALL BE PROPERLY PACKAGED IN A SUITABLE SEALED UNIT CONTAINER CAPABLE OF PROTECTING THE CONTENTS FROM DAMAGE AND/OR BREAKAGE. UNITS SHALL BE PACKED IN SUITABLE COMMERCIAL EXTERIOR (SHIPPING) CONTAINERS (EXPORT WHEN NECESSARY) WHICH SHALL INSURE ACCEPTANCE AND SAFE DELIVERY BY COMMON OR OTHER CARRIER, AT THE LOWEST RATE, TO POINT OF DELIVERY CALLED FOR IN THE CONTRACT OR ORDER. MATERIAL MUST BE MARKED IAW MEDICAL MARKING STANDARD NO. 1. THIS SUPERCEDES ALL REFERENCES CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED: CONTINUED ON NEXT PAGE PAGE 7 OF 24 PAGES SPE2DP-24-T-1875 SECTION B TO MIL-STD-129. COPIES OF MEDICAL MARKING STANDARD NO. 1 (MMS NO. 1) MAY BE OBTAINED BY CONTACTING DLA TROOP SUPPORT VIA EMAIL TO fssb@dla.mil. MMS NO. 1 IS ALSO AVAILABLE ONLINE AT: https://www.dla.mil/Logistics-Operations/Packaging/ RD003, COVERED DEFENSE INFORMATION POTENTIALLY APPLIES FENWAL, INC. 4Q7Q2 P/N 4R0012MC FENWAL, INC. 4Q7Q2 P/N NDC00942-9202-01 CLIN PR PRLI UI QUANTITY UNIT PRICE TOTAL PRICE . 0001 7006933334 0001 PG 1.000 NSN/MATERIAL:6505015998028 DELIVERY (IN DAYS):0020 DELIVER FOB: DESTINATION QTY VARIANCE: PLUS 0% MINUS 0% INSPECTION POINT: DESTINATION ACCEPTANCE POINT: DESTINATION PREP FOR DELIVERY: PKGING DATA-QUP:001 IF MATERIAL IS CONSIDERED HAZARDOUS IAW FED-STD-313, PACKAGE IN ACCORDANCE WITH TQ REQUIREMENT IP025. IF THE MATERIAL IS NOT CONSIDERED HAZARDOUS, IN ACCORDANCE WITH FED-STD-313, THE MATERIAL SHALL BE COMMERCIALLY PACKAGED IN ACCORDANCE WITH ASTM D3951. All DLA Master List of Technical and Quality Requirements take precedence over ASTM D3951. Mark and label all packaging and packing in accordance with MIL-STD-129. The Unit of Issue (U/I) and Quantity per Unit Pack (QUP) will be as specified in the contract/purchase order. PALLETIZATION SHALL BE IN ACCORDANCE WITH RP001: DLA PACKAGING REQUIREMENTS FOR PROCUREMENT BULK BREAK POINT: W68MX4 W0Q1 MADIGAN ARMY MEDICAL CTR FITZSIMMONS BLDG 940A JOINT BASE LEWIS MCCH WA 98431-1100 US SHIP BY TRACEABLE MEANS. DO NOT USE PARCEL POST. FREIGHT SHIPPING ADDRESS: W68MX4 CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED: CONTINUED ON NEXT PAGE PAGE 8 OF 24 PAGES SPE2DP-24-T-1875 SECTION B PR: 7006933334 PRLI: 0001 CONT’D W0Q1 MADIGAN ARMY MEDICAL CTR FITZSIMMONS BLDG 940A JOINT BASE LEWIS MCCH WA 98431-1100 US MARKFOR W68MX4 W0Q1 MADIGAN ARMY MEDICAL CTR FITZSIMMONS BLDG 940A JOINT BASE LEWIS MCCH WA 98431-1100 US M/F: (TCN) W58DQX40790025 RDD: 126 PROJ: TP 3 SUPP ADD: W68MX4 SIG: J FOR GOVERNMENT USE ONLY: (IPD) 13 DIC: A0A DIST: ADV: 2A FC: T4 Need Ship Date:00/00/0000 Original Required Delivery Date:03/26/2024 * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * CONTINUATION SHEET REFERENCE NO. OF DOCUMENT BEING CONTINUED: PAGE 9 OF 24 PAGES CONTINUED ON NEXT PAGE SPE2DP-24-T-1875